But the Tube, with its sturdy reliability and uniformity, offers a security blanket for commuters and tourists. Riders never get stuck in traffic, as you might on a bus. The stops never vary, whether you are watching for original site them or not. The unionized workers that keep the Tube running were less excited about moving to the world of 24/7. Issues were raised about maintenance, security and quality of published here life that took three years to sort out. “The truth is that it is not politicians and their top officials who will deliver a Night Tube for London,” National Union of Rail, Maritime and Transport Workers General-Secretary Mick Cash said in a statement Friday. “It is the cleaners, station staff, drivers, engineers and all the other grades working anti-social hours who will be transforming London into a 24-hour city.” Some 100 British Transport Police officers will patrol the network on Friday and Saturday nights, offering assurance to revelers, commuters and tourists on the system. “It can be a middle-aged clubber like me coming home after a late night out with your missus, not being stressed about the time of the last Tube,” London Mayor Sadiq Khan said. Planning for the change was meticulous.
For the original version including any supplementary images or video, visit http://www.bostonherald.com/news/international/2016/08/24_hour_subways_signal_new_era_for_london_night_owls
And that’s something consultants are in a prime position to advise on. They have access to and the attention of top executives. Kearney has been ‘carbon neutral’ since 2010. “Carbon neutrality”, or having a net zero carbon footprint, refers to achieving net zero carbon emissions by balancing a measured amount of carbon released with an equivalent amount sequestered or offset, or Related Site buying enough carbon credits to make up the difference. Who knows, perhaps a goal of carbon neutrality may bring some balance between consultants’ work and life. Sustainability consultancies are equipped to provide advice on a range of these crucial factors that will make a sustainability agenda work. Kearney. Studies show that taking a partial approach to sustainability is inadequate and often fail. According to the Economist, 55% of the world’s leading companies have policies to reduce energy consumption but 86% of those companies lack the capability to measure and report on their carbon footprint. This will help the communities where companies do business and will bring new revenue streams to businesses, which will maximize RMI.
IndexXa is in development for patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery. Portola is seeking conditional approval of IndexXa in the EU through the centralized procedure. With the acceptance of the application, the EMAs Committee for Medicinal Products for Human Use (CHMP) will now begin the centralized review procedure under a standard 210-day review period. An estimated 73,000 patients treated with an oral Factor Xa inhibitor will be hospitalized this year due to major bleeding or because they require urgent surgery in the EU5i. These patients are critically ill and could potentially benefit from a Factor Xa inhibitor antidote, said Bill Lis, chief executive officer of Portola. As there is currently no approved antidote for Factor Xa inhibitors in the EU, we are working diligently to bring IndexXa to patients. The MAA validation is an important milestone toward achieving that goal. Portolas MAA submission is based on data from two Phase 3 ANNEXA studies that evaluated the safety and efficacy of andexanet alfa in reversing the anticoagulant activity of the Factor Xa inhibitors rivaroxaban and apixaban in healthy volunteers. Results of the ANNEXA studies were published by The New England Journal of Medicine. The MAA also included limited adjudicated efficacy and safety data from initial patients enrolled in the ongoing ANNEXA-4 study. Portola is currently evaluating andexanet alfa in this global, Phase 3b/4 single-arm, open-label study in patients receiving apixaban, rivaroxaban, edoxaban or enoxaparin who present with an acute major bleed. The study is enrolling patients in the United States, Canada and the EU.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/portola-pharmaceuticals-announces-validation-marketing-123000968.html